Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment

RA McCutcheon, RSE Keefe, PK McGuire - Molecular psychiatry, 2023 - nature.com
Cognitive deficits are a core feature of schizophrenia, account for much of the impaired
functioning associated with the disorder and are not responsive to existing treatments. In this …

Neurotransmitters—key factors in neurological and neurodegenerative disorders of the central nervous system

RI Teleanu, AG Niculescu, E Roza… - International journal of …, 2022 - mdpi.com
Neurotransmitters are molecules that amplify, transmit, and convert signals in cells, having
an essential role in information transmission throughout the nervous system. Hundreds of …

Dopamine and glutamate in schizophrenia: biology, symptoms and treatment

RA McCutcheon, JH Krystal, OD Howes - World Psychiatry, 2020 - Wiley Online Library
Glutamate and dopamine systems play distinct roles in terms of neuronal signalling, yet both
have been proposed to contribute significantly to the pathophysiology of schizophrenia. In …

Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments

RS Duman, G Sanacora, JH Krystal - Neuron, 2019 - cell.com
The mechanisms underlying the pathophysiology and treatment of depression and stress-
related disorders remain unclear, but studies in depressed patients and rodent models are …

Economics and mental health: the current scenario

M Knapp, G Wong - World Psychiatry, 2020 - Wiley Online Library
Economics and mental health are intertwined. Apart from the accumulating evidence of the
huge economic impacts of mental ill‐health, and the growing recognition of the effects that …

PV interneurons: critical regulators of E/I balance for prefrontal cortex-dependent behavior and psychiatric disorders

BR Ferguson, WJ Gao - Frontiers in neural circuits, 2018 - frontiersin.org
Elucidating the prefrontal cortical microcircuit has been challenging, given its role in multiple
complex behaviors, including working memory, cognitive flexibility, attention, social …

Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo …

JH Krystal, JM Kane, CU Correll, DP Walling, M Leoni… - The Lancet, 2022 - thelancet.com
Background Emraclidine is a novel, brain-penetrant, highly selective M4 receptor positive
allosteric modulator in development for the treatment of schizophrenia. We aimed to …

Genetic insights into the neurodevelopmental origins of schizophrenia

R Birnbaum, DR Weinberger - Nature Reviews Neuroscience, 2017 - nature.com
Schizophrenia is a severe neuropsychiatric disorder with a longstanding history of
neurobiological investigation. Although the underlying causal mechanisms remain …

Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment

M Wada, Y Noda, Y Iwata, S Tsugawa, K Yoshida… - Molecular …, 2022 - nature.com
Antipsychotic drugs are the mainstay in the treatment of schizophrenia. However, one-third
of patients do not show adequate improvement in positive symptoms with non-clozapine …

Sex differences and the neurobiology of affective disorders

DR Rubinow, PJ Schmidt - Neuropsychopharmacology, 2019 - nature.com
Observations of the disproportionate incidence of depression in women compared with men
have long preceded the recent explosion of interest in sex differences. Nonetheless, the …